Author: Michael Dionne, DNP, PMHNP-BC | Reforge Psychiatry | Updated: April 23, 2026
Table of Contents
TL;DR
- PTSD treatment for veterans works when it matches the veteran’s presentation, life stage, and readiness — not when it follows a one-size sequence.
- First-line trauma-focused therapies (CPT, PE, EMDR) carry the strongest evidence — a Strong for recommendation in the 2023 VA/DoD CPG — but vary significantly in what they ask of the patient.
- Three medications carry Strong for grades in the 2023 VA/DoD CPG: Sertraline, Paroxetine, and Venlafaxine. Prazosin is specifically suggested for nightmare management but not for global PTSD treatment. Benzodiazepines carry a Strong against recommendation.
- Sleep is the highest-leverage, most frequently overlooked treatment target. CBT-I carries a Strong for recommendation in the 2025 VA/DoD Insomnia CPG for veterans with comorbid PTSD.
- Interventional options — TMS, ECT, ketamine infusion — have a role after an adequate first-line trial, not before.
Most veterans come to the question of PTSD treatment having already tried something. Maybe a VA SSRI and four therapy visits that did not click. Maybe a civilian therapist who was kind but unfamiliar with military trauma. Maybe nothing at all — just a decade of working around it.
The honest answer to “what works” is that several things work. Most require more than one round of trying. And the right sequence depends on what you have already tried, what you can tolerate, and what your life looks like right now.
There is no universal first step.
This guide walks through evidence-based options — therapies, medications, sleep, integrative approaches, and interventional psychiatry for treatment-resistant presentations — informed by the current VA/DoD Clinical Practice Guidelines and the best available research. It is written to help veterans and their families understand the landscape well enough to have a real conversation with a provider. Not to replace that conversation.
How PTSD Actually Responds to Treatment
Quick answer: PTSD is highly treatable. Most veterans who engage with appropriate treatment see meaningful improvement. “Meaningful improvement” rarely means symptom disappearance — it means the disorder stops running your life.
Common misunderstanding: Two opposite myths persist. One is that PTSD is a life sentence that treatment manages but never changes. The other is that the right therapy or medication fixes it.
Neither holds up. PTSD symptoms can be substantially reduced in most patients. Full remission is possible, but not the realistic goal for every veteran — especially those with long symptom duration, ongoing stressors, or comorbid conditions like depression or substance use.
Clinical reality: The 2023 VA/DoD Clinical Practice Guideline for PTSD identifies trauma-focused psychotherapies — CPT, PE, and EMDR — as the highest-evidence first-line treatments, carrying a Strong for recommendation. Psychotherapy is explicitly recommended over pharmacotherapy as the primary treatment.
Three medications (Sertraline, Paroxetine, Venlafaxine) also carry Strong for grades as adjunctive support. A substantial minority of patients respond incompletely to first-line care, at which point interventional options become relevant.
In practice: A reasonable expectation is a 30–70% reduction in symptoms with adequate first-line treatment, achieved over weeks to months, with meaningful improvement in occupational and social functioning.
Veterans who do not meet those numbers after an honest trial — adequate dose, adequate duration, active engagement — are candidates for second-line options. Not candidates for giving up.
First-Line Therapies: CPT, PE, and EMDR
Quick answer: Trauma-focused psychotherapies are the highest-evidence treatment for PTSD in veterans. The 2023 VA/DoD CPG gives a Strong for recommendation individually to CPT, PE, and EMDR — and explicitly recommends psychotherapy over medications as the primary approach.
Common misunderstanding: Some veterans believe these therapies are interchangeable — that the choice between them is a scheduling detail. It is not.
CPT emphasizes cognitive restructuring: identifying and challenging trauma-related beliefs about yourself, others, and the world.
Prolonged exposure therapy (PE) requires systematic, repeated exposure to the trauma memory and to avoided situations.
EMDR uses bilateral stimulation while the patient processes trauma material, which many veterans find easier to tolerate than PE’s direct exposure protocol.
Different mechanisms, different tolerability profiles, different demands on the patient.
Clinical reality: The 2023 VA/DoD PTSD CPG evaluated CPT, PE, and EMDR individually — as opposed to earlier guidelines that treated them as a class — and all three retained the same Strong for grade. The guideline explicitly states they are “relatively equally effective” and emphasizes shared decision-making in selecting among them. A broader review of randomized trials in military PTSD populations reached similar conclusions about the relative effectiveness of the major trauma-focused protocols.
The largest head-to-head trial in veterans to date — with 916 participants — found that PE was statistically more effective than CPT, but the difference did not reach the pre-specified threshold for clinical significance (effect size 0.17; threshold 0.25).
Importantly, PE had a significantly higher dropout rate (55.8% vs. 46.6%), suggesting that PE’s statistical edge may partly reflect early completers rather than true superiority. Both produced meaningful improvements.
A closer look at prolonged exposure: PE is worth understanding in more detail, partly because it’s frequently misunderstood. Patients hear the word “exposure” and imagine being forced to relive the worst moment of their life on repeat. The actual protocol is more disciplined than that.
Developed by Edna Foa at the University of Pennsylvania, PE is built on emotional processing theory: trauma memories are maintained by avoidance, and the more you avoid reminders, the more power the memory keeps.
PE systematically breaks that cycle through two coordinated interventions:
- Imaginal exposure — recounting the trauma narrative aloud in session, recorded, and listened to between sessions.
- In vivo exposure — gradually confronting real-world situations that have become avoided (crowded places, driving certain routes, particular smells or sounds).
Repeated engagement in a safe therapeutic context allows the nervous system to relearn that the memory itself is not dangerous. The standard protocol runs 8–15 weekly 90-minute sessions, longer than typical therapy appointments, because the exposure work requires adequate time to engage with and process.
The evidence base is substantial. PE has more randomized controlled trial support than any other PTSD treatment, and a systematic review and meta-analysis in military populations confirmed its effectiveness specifically for service members and veterans. PE is particularly effective for veterans whose presentation is dominated by avoidance symptoms, intrusive memories, and specific trauma-related triggers.
The cost is that it is demanding. Completion rates are lower than those for CPTs, and the first several sessions often lead to increased distress before improvement begins.
A well-trained PE therapist explicitly prepares patients for this curve and provides the stabilization support that prevents dropouts at week three. Finding a therapist with formal PE training — not just “trauma-informed” framing — is the single biggest predictor of whether PE will actually work for a given veteran.
In practice: The best predictor of outcome is not which protocol you use — it is whether you can tolerate and complete the treatment. A veteran who drops out of PE after three sessions gets less benefit than one who completes 12 sessions of CPT.
Ask a prospective therapist: which trauma-focused protocol are you trained in, how many complete cycles have you run, and what do you do when a patient is struggling mid-protocol? Those answers tell you more than the list of credentials.
Medications: What the Evidence Actually Shows
Quick answer: Three medications carry Strong for grades in the 2023 VA/DoD PTSD CPG: Sertraline, Paroxetine, and Venlafaxine. Prazosin is specifically suggested for nightmare management. Benzodiazepines carry a Strong against recommendation. Most other medications are adjunctive or symptom-specific.
Common misunderstanding: Many veterans assume that more medications equal better coverage. The opposite is often true in PTSD.
The condition is under-responsive to the kinds of polypharmacy that help other psychiatric diagnoses. Adding a third or fourth medication to an incomplete PTSD response rarely closes the gap. It frequently introduces side effects that reduce quality of life more than the underlying symptoms do.
Clinical reality: Sertraline and Paroxetine are the only two FDA-approved medications for PTSD. Venlafaxine — an SNRI — carries the same Strong for grade as both in the 2023 VA/DoD PTSD CPG and should be considered alongside them, not below them.
Fluoxetine, despite being an SSRI with supporting evidence base, received Neither for nor against in the 2023 CPG update. Vortioxetine received Weak against.
Prazosin — an alpha-1 blocker originally used for hypertension — has a nuanced position in the current evidence. Earlier studies supported its use for trauma-related nightmares.
The 2018 PACT trial, the largest and most rigorous test — a multicenter VA-funded RCT of 304 veterans — found no significant benefit over placebo for nightmare frequency, sleep quality, or global clinical status.
Despite this, the 2023 VA/DoD PTSD CPG retained prazosin with two distinct grades: Weak against for global PTSD symptom management, but Weak for specifically for nightmare disorder associated with PTSD.
The post-PACT interpretation is that some veterans — particularly those with higher baseline adrenergic activity — do respond, and the totality of evidence across multiple trials justifies selective use for nightmares. The correct clinical framing: mixed evidence, not a reliable option, but a reasonable consideration for nightmare-predominant presentations when first-line options have been tried.
Benzodiazepines carry a Strong against recommendation. The CPG rationale: association with misuse and substance use disorder, reduced effectiveness of recommended PTSD treatments (particularly trauma-focused psychotherapies), and cognitive effects, especially in older patients.
In practice: A reasonable medication trial for PTSD: Sertraline, Paroxetine, or Venlafaxine at an adequate dose for at least 8–12 weeks before concluding non-response. Prazosin is a specific add-on if nightmare disorder is prominent and first-line interventions have been inadequate.
Careful review of everything the patient is already on before adding anything. PTSD medication failure is rarely about the medication — more often it reflects inadequate dose, premature discontinuation, or an expectation mismatch about what medications actually do in PTSD.
Sleep and Nightmares: The Highest-Leverage Target
Quick answer: Sleep problems are near-universal in PTSD and function as both a symptom and an amplifier of every other symptom. Treating sleep well is one of the highest-leverage moves available — and one of the least frequently offered.
Common misunderstanding: Sleep hygiene handouts are not sleep treatment. Cognitive Behavioral Therapy for Insomnia (CBT-I) is.
Most veterans with PTSD-related sleep problems have never been offered CBT-I, because it takes more time and clinical effort to deliver than a checklist.
Clinical reality: CBT-I carries a Strong for recommendation in the 2025 VA/DoD Clinical Practice Guideline for Chronic Insomnia Disorder and is supported for use in veterans with comorbid PTSD.
One important caveat: the 2025 Insomnia CPG notes that CBT-I should be delayed when a patient is actively engaged in exposure-based PTSD therapy, as CBT-I’s sleep restriction component can interfere with trauma processing. The sequencing matters.
Prazosin remains a Weak for option specifically for nightmare disorder. CBT-I combined with appropriate pharmacotherapy when indicated often produces better outcomes than either alone.
Sleep-related medications veterans frequently end up on — trazodone, low-dose quetiapine, zolpidem-class hypnotics — have varying evidence profiles and are not first-line options per CPG guidance.
Sleep apnea is significantly underdiagnosed in veterans with PTSD. The two conditions share overlapping symptoms, and untreated sleep apnea makes every PTSD symptom worse. A sleep study is often the most consequential missing step in an incomplete treatment response.
In practice: If you have significant sleep complaints and have not had a formal sleep evaluation, that is the most obvious gap in your care. Treating sleep well frequently unlocks daytime improvements that therapy alone could not reach.
It is also the least trauma-disclosive intervention. A veteran who is not ready for PE or CPT can make meaningful progress on sleep before directly engaging the trauma narrative.
Integrative and Complementary Treatments
Quick answer: Select integrative approaches — structured yoga, mindfulness protocols, and evidence-informed supplementation — have supporting evidence as adjuncts. The 2023 VA/DoD PTSD CPG gives a Weak for to mind-body interventions including yoga for PTSD. They do not replace first-line care.
Common misunderstanding: Some veterans reach for integrative approaches because conventional care has been disappointing, then treat the integrative approach as a standalone solution.
The evidence does not support standalone use for moderate-to-severe PTSD. The evidence does support thoughtful integration alongside first-line therapies.
Clinical reality: Trauma-sensitive yoga has a modest but growing evidence base. The 2023 VA/DoD PTSD CPG includes a Weak for recommendation for mind-body interventions.
Mindfulness-Based Stress Reduction (MBSR) shows improvement in arousal and avoidance symptoms, though less robustly than trauma-focused psychotherapy.
Omega-3 fatty acids (particularly EPA) have evidence for depressive symptoms and supporting data in PTSD-related mood disturbance. N-acetylcysteine (NAC) has preliminary evidence for PTSD and co-occurring substance use. Magnesium glycinate is well-tolerated, supports sleep architecture, and has modest evidence for anxiety-adjacent symptoms.
In practice, integrative approaches work best as quality-of-life enhancers that make first-line treatment more sustainable — lower baseline arousal, better sleep, and greater capacity to engage with trauma-focused therapy.
A veteran doing CPT plus a structured yoga program plus targeted supplementation is likely to have a better experience than one doing CPT alone. None of the integrative pieces is the treatment. Together, they can make the treatment more tolerable and more durable.
Interventional Psychiatry for Treatment-Resistant Cases
Quick answer: When first-line care has been adequately tried and the response is incomplete, interventional psychiatric modalities become appropriate. The 2023 VA/DoD PTSD CPG gives a Neither for nor against grade to TMS — reflecting insufficient evidence, not evidence of harm. ECT has strong evidence for severe depression. Ketamine infusion is specifically endorsed in a separate VA/DoD guideline.
Common misunderstanding: Interventional psychiatry is often framed as a last resort or extreme. For the patient for whom it is appropriate, it is simply the next evidence-based step after first-line care has been completed without sufficient response.
Clinical reality: TMS (repetitive transcranial magnetic stimulation) has FDA approval for major depressive disorder, OCD, and several other indications — but not PTSD as of April 2026.
The 2023 VA/DoD PTSD CPG rates TMS as Neither for nor against due to insufficient evidence. However, active research continues, and off-label use for PTSD with comorbid MDD provides a legitimate clinical and billing pathway.
ECT remains one of the most effective treatments available for severe depression and treatment-resistant presentations, including those with suicidal ideation. Cognitive side effects deserve careful discussion, but ECT’s effectiveness profile in the right patient is substantial.
Ketamine infusion occupies a specific, narrow endorsement in the evidence base. The 2024 VA/DoD Clinical Practice Guideline for Suicide Risk Management gives a Weak for recommendation for ketamine infusion as an adjunctive treatment for short-term reduction in suicidal ideation in patients with MDD — not for PTSD broadly, not as monotherapy, and not as a means of preventing suicide attempts or deaths.
That distinction is important. The MIRECC implementation summary describes moderate evidence for acute SI reduction within 24 hours, with effects observed up to six weeks.
In practice: Interventional options require careful discussion of indications, access, cost, and what “treatment-resistant” actually means for this specific patient.
A veteran who tried one SSRI for six weeks is not treatment-resistant — they have had an incomplete first-line trial.
A veteran who has completed adequate trials of two medications from the Strong for category, completed a course of trauma-focused therapy, and still has significant functional impairment is a different clinical profile — and the one for whom interventional conversations become appropriate.
How to Sequence and Combine Treatments
Quick answer: The best outcomes come from combined, sequenced care — not from picking a single winner. The 2023 VA/DoD PTSD CPG explicitly recommends psychotherapy as the primary approach, with medication as adjunctive support, and emphasizes shared decision-making throughout.
In practice: A reasonable first-line combination for a veteran with PTSD and sleep complaints looks like this:
- Sertraline or Venlafaxine at the target dose
- CBT-I for insomnia (after completing acute trauma-focused therapy)
- CPT or EMDR with a trained therapist
- Sleep study if sleep apnea is suspected
- Prazosin if nightmare disorder is prominent
A second pass, if the response is inadequate, adds or rotates modalities based on what did and did not help. Integrative supports — yoga, targeted supplementation — layered in as stabilizers. Interventional options after a complete and honest first-line trial.
The sequence matters. So does the willingness to change the sequence when something is not working. That is usually the more important clinical skill on both the provider and patient sides.
Key Takeaways
- The 2023 VA/DoD PTSD CPG recommends CPT, PE, and EMDR individually at Strong for grade — and explicitly recommends psychotherapy over medications as the primary treatment.
- Three medications carry Strong for grades: Sertraline, Paroxetine, and Venlafaxine. Prazosin is Weak for nightmares only, Weak against for global PTSD. Benzodiazepines are Strong against.
- CBT-I carries a Strong for recommendation in the 2025 VA/DoD Insomnia CPG for veterans with PTSD. Sleep is the most frequently overlooked high-leverage target.
- TMS is not FDA-approved for PTSD and carries Neither for nor against in the PTSD CPG. Ketamine infusion has a Weak for grade for short-term SI reduction in SI+MDD — not for PTSD broadly and not as suicide prevention.
- First-line therapy means adequate dose, adequate duration, and active engagement. Most veterans who don’t respond haven’t had all three.
- Sequenced, combined care outperforms any single modality. The right combination depends on the individual veteran’s presentation, comorbidities, and what they can actually sustain.
FAQ
How long does PTSD treatment take to work for veterans?
Most veterans who respond to first-line care see meaningful improvement within 8–16 weeks, though the timeline varies considerably.
Trauma-focused psychotherapies typically run 10–16 structured sessions. Medication trials (Sertraline, Paroxetine, Venlafaxine) need at least 8–12 weeks at an adequate dose before you can conclude response or non-response.
Full treatment courses often span 4–12 months. Some veterans benefit from maintenance therapy beyond that, particularly those with long symptom duration or ongoing stressors.
The goal in the first 12 weeks is meaningful functional improvement — not full resolution.
Does online PTSD treatment actually work for veterans?
Yes, with qualifications.
Telehealth-delivered trauma-focused therapy has evidence comparable to in-person delivery for most veterans, and the accessibility advantage is real — especially for veterans in rural areas, those with transportation barriers, or those for whom in-person settings are triggering.
The caveats: telehealth is less appropriate for severely destabilized patients or those who need close-interval medical monitoring.
Asking a prospective online provider how they handle crises, what their after-hours protocol is, and which specific trauma-focused protocol they use are reasonable screening questions before you book.
Can I do trauma therapy if I’m still drinking or using?
You can, with the right provider and an honest plan.
Abstinence is not a prerequisite for all trauma-focused therapies. But active heavy use can significantly interfere with treatment gains — partly because it affects memory consolidation, and partly because substance use is often serving the same avoidance function that therapy is designed to address.
Integrated dual-diagnosis approaches (treating PTSD and substance use simultaneously) consistently outperform serial care — treating substance use first, then PTSD — in outcomes research.
Start with an honest conversation with a provider about what you are using, how often, and what you want to change.
Are there PTSD treatments that don’t require talking about the trauma?
Yes.
Medication management, CBT-I for sleep, prazosin for nightmares, yoga programs with evidence in PTSD, mindfulness protocols, and some Internal Family Systems approaches can all produce meaningful benefits without a detailed trauma narrative.
These are not always the most powerful options, but they are legitimate entry points for veterans who are not ready for exposure-based therapy. Starting here and building toward trauma-focused work later is a reasonable and well-supported sequence.
Many veterans find that reducing sleep disruption and baseline arousal first makes the trauma-focused work more tolerable when they are ready.
What should I look for in a provider who treats veterans?
Three things matter most.
First: specific training in CPT, PE, or EMDR — not just “trauma-informed” as a general orientation, but structured protocol training with clinical supervision.
Second: genuine familiarity with military culture without relying on clichés about it. A provider who says they “specialize in veterans” but cannot tell you what CPT stands for is not the right fit.
Third: willingness to treat the whole clinical picture — sleep, mood, substance use, occupational functioning — not just the piece that fits their preferred modality.
Credentials matter less than whether the provider listens carefully, asks concrete functional questions, and can articulate a treatment plan that makes sense to you.
The Bottom Line
PTSD treatment for veterans is one of the more successful areas of psychiatry. Most veterans who engage with appropriate, sustained care get meaningfully better.
The barrier is rarely that the treatments don’t work. It’s that assembling a competent, patient-fit combination is harder than it should be.
If you want to talk through where your current treatment plan might have gaps, or what a realistic next step looks like, you can book a free 15-minute consult.
This article is for educational purposes only and does not constitute medical or legal advice. Always consult a licensed provider for guidance specific to your situation. If you are in crisis, call or text 988 (Veterans: press 1) or go to your nearest emergency department.
Michael Dionne, DNP, PMHNP-BC, is the founder of Reforge Psychiatry. He is a board-certified psychiatric mental health nurse practitioner and U.S. Army veteran specializing in PTSD treatment, medication management, and telehealth psychiatry for veterans and first responders. Licensed in California, New Hampshire, New York, Illinois, and Idaho.
References
- American Psychological Association. Clinical Practice Guideline for the Treatment of PTSD: Prolonged Exposure. https://www.apa.org/ptsd-guideline/treatments/prolonged-exposure
- Foa, E. B., & Kozak, M. J. (1986). Emotional processing of fear: Exposure to corrective information. Psychological Bulletin, 99(1), 20–35. https://pubmed.ncbi.nlm.nih.gov/2871574/
- Foa, E. B., Hembree, E. A., Rothbaum, B. O., & Rauch, S. A. M. (2019). Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences (2nd ed.). Oxford University Press. https://global.oup.com/academic/product/prolonged-exposure-therapy-for-ptsd-9780190926939
- McLean, C. P., Levy, H. C., Miller, M. L., & Tolin, D. F. (2022). Exposure therapy for PTSD in military populations: A systematic review and meta-analysis of randomized clinical trials. Journal of Anxiety Disorders, 90, 102607. https://pubmed.ncbi.nlm.nih.gov/35738046/
- Powers, M. B., Halpern, J. M., Ferenschak, M. P., Gillihan, S. J., & Foa, E. B. (2010). A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clinical Psychology Review, 30(6), 635–641. https://pubmed.ncbi.nlm.nih.gov/20546985/
- Raskind, M. A., Peskind, E. R., Chow, B., Harris, C., Davis-Karim, A., Holmes, H. A., et al. (2018). Trial of prazosin for posttraumatic stress disorder in military veterans. New England Journal of Medicine, 378(6), 507–517. https://pubmed.ncbi.nlm.nih.gov/29414272/
- Resick, P. A., Monson, C. M., & Chard, K. M. (2024). Cognitive Processing Therapy for PTSD: A Comprehensive Therapist Manual (2nd ed.). Guilford Press. https://www.guilford.com/books/Cognitive-Processing-Therapy-for-PTSD/Resick-Monson-Chard/9781462554270
- Schnurr, P. P., Chard, K. M., Ruzek, J. I., Chow, B. K., Resick, P. A., Foa, E. B., et al. (2022). Comparison of prolonged exposure vs cognitive processing therapy for treatment of posttraumatic stress disorder among U.S. veterans: A randomized clinical trial. JAMA Network Open, 5(1), e2136921. https://pubmed.ncbi.nlm.nih.gov/35044471/
- Steenkamp, M. M., Litz, B. T., Hoge, C. W., & Marmar, C. R. (2015). Psychotherapy for military-related PTSD: A review of randomized clinical trials. JAMA, 314(5), 489–500. https://pubmed.ncbi.nlm.nih.gov/26241600/
- U.S. Department of Veterans Affairs. National Center for PTSD — PTSD Treatment. https://www.ptsd.va.gov/understand_tx/
- U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. https://www.healthquality.va.gov/guidelines/MH/ptsd/
- U.S. Department of Veterans Affairs & U.S. Department of Defense. (2024). VA/DoD Clinical Practice Guideline for the Assessment and Management of Patients at Risk for Suicide, Version 3.0. https://www.healthquality.va.gov/guidelines/MH/srb/
- U.S. Department of Veterans Affairs & U.S. Department of Defense. (2025). VA/DoD Clinical Practice Guideline for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea. https://www.healthquality.va.gov/guidelines/CD/insomnia/
- Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., et al. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. American Journal of Psychiatry, 175(2), 150–158. https://pubmed.ncbi.nlm.nih.gov/28969441/
Related Reading
PTSD Disability Rating: What Your Psychiatric Documentation Actually Controls
Why PTSD Medication Fails Most Veterans — And What Works Instead